lung cancer
Conditions
Interventions
experimental group:The dosage of gefitinib was 250mg, Po, QD, and apatinib mesylate 250mg / 500mg, QD, Po
Sponsors
Ruikang Hospital Affiliated to Guangxi University of traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old, both male and female; 2. EGFR positive patients with advanced NSCLC, including: The first-line treatment for patients with recurrence or metastasis (patients with recurrence within 6 months after completion of adjuvant treatment are allowed to be included in the study); Note: chemotherapy or EGFR TKIs is is allowed for adjuvant therapy. Patients who can continue to use EGFR TKIs after the progression of first-line EGFR TKIs treatment; 3. Volunteer to participate in the study and sign informed consent; 4. Researchers believe that it can benefit.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with contraindications to apatinib or EGFR TKIs (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, uncontrolled hypertension, grade III-IV cardiac insufficiency, within 30 days after major surgery, severe hepatic and renal insufficiency, etc.) 3. The doctors think it is not suitable to be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR;DCR;DOR; | — |
Countries
China
Contacts
Public ContactHou Encun
Ruikang Hospital Affiliated to Guangxi University of traditional Chinese Medicine
Outcome results
None listed